GERON CORP Accrued Liabilities, Current
GERON CORP (GERN) had Accrued Liabilities, Current of $30.71 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $30.71M.
- 2026-03-31: Accrued Liabilities, Current $30.96M.
- 2025-12-31: Accrued Liabilities, Current $51.34M.
- 2025-09-30: Accrued Liabilities, Current $39.93M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $30.71M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $30.96M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $51.34M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $39.93M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $26.29M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $28.89M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $35.55M 10-K · filed 2026-03-02 |
| 2024-09-30 | $36.49M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $38.66M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $33.89M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $40.31M 10-K · filed 2025-02-27 |
| 2023-09-30 | $41.86M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $45.04M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $34.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $33.10M 10-K · filed 2024-02-28 |
| 2022-09-30 | $53.11M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $30.67M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $35.80M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $29.83M 10-K · filed 2023-03-16 |
| 2021-09-30 | $26.25M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $27.15M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $19.76M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $14.93M 10-K · filed 2022-03-10 |
| 2020-09-30 | $13.99M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $10.29M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $10.04M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $7.53M 10-K · filed 2021-03-11 |
| 2019-09-30 | $4.83M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $3.24M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.04M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.32M 10-K · filed 2020-03-12 |
| 2017-12-31 | $926.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $1.11M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $856.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.05M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $1.43M 10-K · filed 2018-03-16 |
| 2016-09-30 | $1.43M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.13M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $1.07M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.12M 10-K · filed 2017-03-01 |
| 2015-09-30 | $727.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $933.00K 10-Q · filed 2015-08-05 |
| 2015-03-31 | $1.38M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.54M 10-K · filed 2016-03-10 |
| 2014-09-30 | $2.02M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $1.06M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $1.29M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $1.78M 10-K · filed 2015-03-11 |
| 2013-09-30 | $1.99M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $1.36M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $2.59M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $3.48M 10-K · filed 2014-03-17 |
| 2012-09-30 | $4.17M 10-Q · filed 2012-11-02 |
| 2012-06-30 | $4.38M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $4.38M 10-Q · filed 2012-05-07 |
| 2011-12-31 | $3.64M 10-K · filed 2013-03-15 |
| 2011-09-30 | $3.00M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $3.07M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $2.64M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |